Free Trial

Oxford BioMedica (OTCMKTS:OXBDF) Trading 6.1% Higher - What's Next?

Oxford BioMedica logo with Medical background

Key Points

  • Oxford BioMedica's shares rose 6.1% on Thursday, reaching a price of $7.80, significantly increasing trading volume to approximately 20,000 shares.
  • The stock's fifty-day moving average price is $6.43, while the two-hundred-day moving average stands at $4.84, indicating recent positive momentum.
  • Oxford BioMedica specializes in contract development and manufacturing, focusing on its LentiVector platform for advanced gene delivery systems.
  • MarketBeat previews top five stocks to own in October.

Oxford BioMedica (OTCMKTS:OXBDF - Get Free Report) shares rose 6.1% on Thursday . The stock traded as high as $7.80 and last traded at $7.80. Approximately 20,000 shares were traded during trading, an increase of 57,207% from the average daily volume of 35 shares. The stock had previously closed at $7.35.

Oxford BioMedica Trading Up 6.1%

The firm's fifty day moving average price is $6.43 and its two-hundred day moving average price is $4.84.

About Oxford BioMedica

(Get Free Report)

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Oxford BioMedica Right Now?

Before you consider Oxford BioMedica, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford BioMedica wasn't on the list.

While Oxford BioMedica currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.